Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Breast Cancer Research

Volumn 7, Issue 3, 2005, Pages

  Wegman, Pia ^a   Vainikka, Linda ^a   Stål, Olle ^a   Nordenskjöld, Bo ^a   Skoog, Lambert ^b   Rutqvist, Lars Erik ^b   Wingren, Sten ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; CYP2D6; Polymorphism; SULT1A1; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; SULFOTRANSFERASE 1A1; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ARYL SULFOTRANSFERASE; SULT1A1 PROTEIN, HUMAN;

AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CYP2D6 GENE; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PREDICTIVE VALUE; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SULT1A1 GENE; SURVIVAL ANALYSIS; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADULT; BREAST TUMOR; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; SAMPLE SIZE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RECURRENCE; RISK FACTORS; SAMPLE SIZE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 29144491089     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr993     Document Type: Article

References (24)

1. Early Breast Cancer Trialist's Collaborative Group (EBCTCG): Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 352: 1451-1467.
2. Fuqua SAW, Wiltschke C, Zhang QX, Borg Å, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred C: Hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res. 2000, 60: 4026-4029.
3. McClelland RA, Barrow D, Madden T-A, Dutkowski CM, Pamment J, Knowlden JM, Gee JMW, Nicholson RI: Enhanced epidermal growth factor receptor signalling in MCF-7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology. 2001, 142: 2776-2788. 10.1210/en.142.7.2776.
4. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 Cells. Endocrinology. 2003, 144: 1032-1044. 10.1210/en.2002-220620.
5. Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev. 2002, 2: 101-112. 10.1038/nrc721.
6. Fabian C, Tilzer L, Sternson L: Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharma Drug Dispos. 1981, 2: 381-390.
7. Coezy E, Borgna J-L, Rochefort H: Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 1982, 42: 317-323.
8. Dehal SS, Kupfer D: CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 1997, 57: 3402-3406.
9. Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White INH: Identification of CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis. 2002, 23: 1897-1901. 10.1093/carcin/23.11.1897.
10. Falany CN, Wheeler J, Oh TS, Falany JL: Steroid sulfation by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol. 1994, 48: 369-375. 10.1016/0960-0760(94)90077-9.
11. Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, et al: Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res. 2000, 60: 6859-6863.
12. Sachse C, Brockmöller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997, 60: 284-295.
13. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB: Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst. 2002, 94: 1635-1640.
14. 1934 A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. Am J Hum Genet. 1990, 47: 994-1001.
15. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM: Phenol sulfotransferase pharmacogenetics in humans: Association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun. 1997, 239: 298-304. 10.1006/bbrc.1997.7466.
16. Rutqvist L-E, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, Somell A, Theve T, Askergren J, Friberg S, et al: Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials. Int J Radiat Oncol Biol Phys. 1989, 16: 629-639.
17. Coughtrie MWH, Gilissen RAHJ, Shek B, Strange RC, Fryer AA, Jones PW, Bamber DE: Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J. 1999, 337: 45-49. 10.1042/0264-6021:3370045.
18. Longcope C, Flood C, Tast J: The metabolism of estrone sulphate in the female rhesus monkey. Steroids. 1994, 59: 270-273. 10.1016/0039-128X(94)90112-0.
19. Coller JK, Krebsfanger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nüssler A, Neuhaus P, Zanger UM, Eichelbaum M, Mürdter TE: The influence of CYP2B6, CYP2C9, and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol. 2002, 54: 157-167. 10.1046/j.1365-2125.2002.01614.x.
20. Stearns V, Johnson M, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003, 95: 1758-1764.
21. Crewe KH, Ellis W, Lennard MS, Tucker GT: Variable contribution of cytochrome P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol. 1997, 53: 171-178. 10.1016/S0006-2952(96)00650-8.
22. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002, 3: 229-243. 10.1517/14622416.3.2.229.
23. Raimundo S, Fisher J, Eichelbaum M, Griese EU, Schwab M, Zang U: Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics. 2000, 10: 577-581. 10.1097/00008571-200010000-00001.
24. Linder MW, Prough RA, Valdes R: Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem. 1997, 43: 254-266.